Neonatal withdrawal syndrome following in utero exposure to paroxetine, clonazepam and olanzapine.
We describe a full-term infant with failed respiratory effort and decerebrate posturing following in utero exposure to paroxetine. All signs and symptoms associated with the paroxetine exposure were resolved by the second day of life. Upon discharge, the infant revealed a normal neurodevelopmental examination.
Murray
K L
KL
Department of Pharmacy, Centennial Medical Center, Nashville, TN 37203, USA. kara.bazzie@hcahealthcare.com
Miller
K M
KM
Pearson
D L
DL
D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects*; D001569:Benzodiazepines / Q000009:adverse effects; D002998:Clonazepam / Q000009:adverse effects; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D009357:Neonatal Abstinence Syndrome / Q000175:diagnosis* / Q000209:etiology; D000077152:Olanzapine; D017374:Paroxetine / Q000009:adverse effects*; D012131:Respiratory Insufficiency / Q000139:chemically induced*; D020230:Serotonin Syndrome / Q000139:chemically induced*
D018687:Antidepressive Agents, Second-Generation; D001569:Benzodiazepines; D017374:Paroxetine; D002998:Clonazepam; D000077152:Olanzapine